We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
+82.64%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$41.3M
AUM Growth
+$6.07M
Cap. Flow
-$624K
Cap. Flow %
-1.51%
Top 10 Hldgs %
99.35%
Holding
14
New
1
Increased
2
Reduced
2
Closed
2

Top Buys

Rank Stock Value
1
ATRS
Antares Pharma, Inc.
ATRS
+$463K
2
TYME
Tyme Technologies, Inc. Common Stock
TYME
+$261K

Top Sells

Rank Stock Value
1
NVLN
Novelion Therapeutics Inc. Common Shares
NVLN
+$1.07M
2
AMRN
Amarin Corp
AMRN
+$189K

Sector Composition

Rank Sector Weight
1 Healthcare 93.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
1
Gilead Sciences
GILD
$165B
$7.72M 18.67%
100,000
– –
AMRN
2
Amarin Corp
AMRN
$297M
$7.32M 17.71%
22,500
-2,500
-10% -$189K
TYME
3
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
$6.05M 14.62%
2,175,000
+100,000
+5% +$261K
GSK icon
4
GSK
GSK
$107B
$4.02M 9.71%
80,000
– –
AGN
5
DELISTED
Allergan plc
AGN
$3.81M 9.21%
20,000
– –
LAB icon
6
Standard BioTools
LAB
$342M
$3.37M 8.15%
450,000
– –
NVLN
7
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$2.99M 7.24%
1,011,487
-301,900
-23% -$1.07M
VKTX icon
8
Viking Therapeutics
VKTX
$3.88B
$2.61M 6.32%
150,000
– –
BIS icon
9
ProShares UltraShort NASDAQ Biotechnology
BIS
$2.28M
$2.35M 5.67%
18,750
– –
ATRS
10
DELISTED
Antares Pharma, Inc.
ATRS
$840K 2.03%
250,000
+150,000
+150% +$463K
LCI
11
CALL
DELISTED
Lannett Company, Inc.
LCI
$238K 0.58%
+12,500
New +$476K
SEEL
12
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
$31K 0.08%
1
– –
AMRN
13
CALL
Amarin Corp
AMRN
$297M
– –
-5,000
Closed -$309K
ATRS
14
CALL
DELISTED
Antares Pharma, Inc.
ATRS
– –
-100,000
Closed -$258K

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q3 2018 Portfolio in Review

As of Q3 2018, Healthcare Value Capital held 14 positions worth $41.3M, up 17% from $35.3M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Healthcare Value Capital's Q3 2018 filing shows 1 new, 2 increased, 2 reduced and 2 closed positions. The largest sale was Novelion Therapeutics Inc. Common Shares, an estimated $1.07M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 90% a quarter earlier.

  • Healthcare Value Capital added most to Antares Pharma, Inc. in Q3 2018, an estimated $463K increase.
  • Healthcare Value Capital's biggest Q3 2018 reduction was Novelion Therapeutics Inc. Common Shares, cutting an estimated $1.07M.
  • Healthcare Value Capital's ten largest holdings make up 99% of its $41.3M portfolio in Q3 2018.
  • Healthcare Value Capital opened 1 new position and closed 2 in Q3 2018.
  • Healthcare Value Capital's portfolio value rose 17% quarter-over-quarter to $41.3M.

Based on Healthcare Value Capital's 13F filing for Q3 2018, filed 14 Nov 2018.